Trends in the development of remdesivir based inventions against COVID-19 and other disorders: A patent review | Zendy

Mohd Imran | Zendy; Ahmed Subeh Alshrari | Zendy; Syed Mohammed Basheeruddin Asdaq | Zendy; Abida Khan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Trends in the development of remdesivir based inventions against COVID-19 and other disorders: A patent review

Author(s) -

Mohd Imran,

Ahmed Subeh Alshrari,

Syed Mohammed Basheeruddin Asdaq,

Abida Khan

Publication year - 2021

Publication title -

journal of infection and public health

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.983

H-Index - 35

eISSN - 1876-035X

pISSN - 1876-0341

DOI - 10.1016/j.jiph.2021.06.013

Subject(s) - covid-19 , medicine , intensive care medicine , virology , pathology , disease , infectious disease (medical specialty) , outbreak

The development of remdesivir has been a breakthrough for COVID-19 treatment. It has been approved in about 50 countries, including Saudi Arabia, since 2020. The generic structure of remdesivir was first disclosed in 2009. This patent review summarizes the remdesivir based inventions to treat/prevent COVID-19 and other disorders from 2009 to May 16, 2021, emphasizing the patents related to medical and pharmaceutical sciences. The primary patents/patent applications of remdesivir are related to its compositions, new combinations with other therapeutic agents, delivery systems, and new indications. The inventive combinations have displayed synergistic effects against COVID-19, whereas the delivery systems/compositions have improved patient compliance. The inventions related to new indications of remdesivir to treat Ebola, hepatitis, idiopathic pulmonary fibrosis, diabetic nephropathy, and cardiovascular complications enhance its therapeutic area. Many new innovative combinations and delivery systems of remdesivir are anticipated to provide better treatment for COVID-19.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research